Chalcone-benzoxaborole hybrids as novel anticancer agents

Area of Science:

• Medicinal Chemistry
• Organic Synthesis
• Pharmacology

Background:

• Chalcones are known for their diverse biological activities, including anticancer properties.
• Benzoxaboroles are a class of compounds with emerging therapeutic potential.
• Hybrid molecules combining different pharmacophores can lead to enhanced efficacy.

Purpose of the Study:

• To synthesize novel chalcone-benzoxaborole hybrid molecules.
• To evaluate the in vitro anticancer activity and toxicity of these compounds.
• To explore the potential of benzoxaboroles in anticancer drug discovery.

Main Methods:

• Synthesis of a series of chalcone-benzoxaborole hybrid molecules.
• Anticancer potency evaluation using three human cancer cell lines (e.g., SKOV3).
• Toxicity assessment on two normal human cell lines.

Main Results:

• Compound 15 (4-fluoro) exhibited the highest potency with an IC50 of 1.4μM against SKOV3 cells.
• Compounds 18 (4-iodo) and 47 (3-methyloxy-4-amino) demonstrated good anticancer activity on SKOV3 cells.
• Compounds 18 and 47 showed low toxicity against normal cell lines, indicating a favorable therapeutic window.

Conclusions:

• Chalcone-benzoxaborole hybrids represent a promising new class of anticancer agents.
• Specific compounds, notably 15, 18, and 47, display significant anticancer potential.
• This study validates the utility of benzoxaboroles in the development of novel cancer therapeutics.